Natco Pharma Ltd.

Natco Pharma has launched the first generic version of Nexavar (Sorafenib) Tablets in 200 mg strength today in the U.S. market. The product will be launched by Natco's commercial partner Viatris, a global pharmaceutical company.

Sorafenib is prescribed for treatment of unresectable Hepatocellular Carcinoma (HCC), advanced Renal Cell Carcinoma (RCC) and Differentiated Thyroid Carcinoma (DTC). Nexavar registered sales of $69.7 million for the year ending December 2021 as per industry sales data.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.